权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Comprehensive Assessment of Retinal Vasculature (CARV)

视网膜血管系统综合评估（CARV）

基本信息

批准号：
8644662
负责人：
Vinayak S Joshi
金额：
$ 15.23万
依托单位：
VISIONQUEST BIOMEDICAL, LLC
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-03-01 至 2015-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8644662
关键词：
Address Agreement Algorithms Area Arteries Blood Vessels Caliber Cardiovascular Diseases Classification Clinical Copper Databases Detection Diabetic Retinopathy Doctor of Philosophy Effectiveness Embolism Environment Evaluation Reports Event Eye Future Goals Gold Health Healthcare Hypertension Hypertensive Retinopathy Image Incidence Institutes Lesion Life Manuals Measurement Measures Methods Ophthalmology Optic Disk Pattern Performance Phase Physician Executives Principal Investigator Process Provider Reader Reporting Research Retina Retinal Retinal Diseases Risk Rural Community Scientist Silver Software Tools South Texas Specialist Stroke System Systemic disease Techniques Telemedicine Time Training Veins Vision cost diabetic experience graphical user interface innovation programs public health relevance retina blood vessel structure screening tool

项目摘要

Summary Teleretinal programs have expanded in recent years, primarily to screen for diabetic retinopathy. Accurate and consistent assessment of the retinal vasculature, which often sustains damage as a result of cardiovascular disease, would advance teleretinal screening in terms of robustness and cost. Unfortunately, assessing changes to the retinal vasculature and quantifying abnormalities in retinal images has proven more difficult. Semi-automatic methods are reported to reduce grader variability, but they are time-consuming, requiring extensive reader interaction, thus limiting the overall effectiveness of a teleretinal screening program. VisionQuest Biomedical and its collaborator, the Retina Institute of South Texas (RIST), will demonstrate a software tool for comprehensive assessment of retinal vasculature (CARV) to aid readers in the quantitative characterization of vascular abnormalities and identification of those images with features indicative of potential sight-threatening or life-threatening conditions. CARV will provide the reader real-time artery to vein ratio (AVR) measurements, an accepted clinical value for determining risk of future stroke or hypertensive events, as well as measurements associated with branching patterns and tortuosity. It will also incorporate detection algorithms for features such as copper and silver wiring, AV nicking, and emboli. Our goal is to provide an aid to the retinal grader for detecting and quantifying common retinal vessel abnormalities with high agreement with the gold standard, a retinal specialist. In this Phase I we will also implement clinically accepted quantitative measurements for vasculature parameters. CARV, which can be integrated into a teleretinal system for diabetics, will allow graders to consistently identify signs of hypertensive retinopathy and CVD-related conditions and providers to exploit the full potential of teleretinal screening.

总结 Teleretinal项目近年来已经扩大，主要用于筛查糖尿病视网膜病变视网膜血管系统的准确和一致的评估，这往往维持由于心血管疾病造成的损害，将推进远程视网膜筛查，鲁棒性和成本。不幸的是，评估视网膜血管系统的变化并量化视网膜图像的异常被证明是更困难的。报道了半自动方法以减少评分员的变化，但它们是耗时的，需要大量的读者因此，限制了远程视网膜筛查程序的整体有效性。 VisionQuest Biomedical及其合作者南德克萨斯州视网膜研究所（RIST）将演示一个软件工具，用于全面评估视网膜血管系统（CARV），以帮助读者在定量表征血管异常和识别这些具有指示潜在视力威胁或生命威胁状况的特征的图像。 CARV将为阅片师提供实时动脉-静脉比（AVR）测量值，确定未来卒中或高血压事件风险的临床价值，以及与分支模式和弯曲度相关的测量。它还将纳入用于诸如铜和银布线、AV切口和栓塞的特征的检测算法。我们本发明的目的是为视网膜分级者提供用于检测和量化常见视网膜病变的辅助手段，血管异常与视网膜专家的黄金标准高度一致。在这第一阶段，我们还将实施临床上接受的血管定量测量参数 CARV可以集成到糖尿病患者的远程视网膜系统中，持续识别高血压视网膜病变和CVD相关疾病的体征，提供者开发远程视网膜筛查的全部潜力。